EMD Millipore acquired a nonexclusive license to iPS Academia Japan’s (AJ) induced pluripotent stem cell (iPSC) patent portfolio, for the development and commercialization of iPSCs for research applications. AJ’s patent portfolio is founded on work by Shinya Yamanaka M.D., at the Center for iPS Cell Research and Application at Kyoto University, to which AJ is an affiliate.

The four cell reprograming factors discovered by Dr. Yamanaka are integral to Millipore’s existing Stemcca™ reprogramming kit for generating human and mouse iPSCs, which uses a single, excisable polycistronic lentiviral vector to deliver the factors.

Under terms of the new licensing deal Millipore will continue to offer the Stemcca kits for research applications. “To collaborate with the founder of iPS cell discovery provides the ideal opportunity for EMD Millipore to build upon our current product offering of the Stemcca reprogramming kits, as well as further advance our research and discovery in the area of stem cell technology, and to provide our customers with the tools necessary in this important, breakthrough area of stem cell research,” states John Sweeney, head of Millipore’s bioscience business unit.

Previous articleBionomics Buys Eclipse for CSC Platform
Next articleFDA Okays Meridian’s Strep Throat Diagnostic